RETRACTED ARTICLE: Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma

Li, Renzeng; Wang, Limin

doi:10.1186/s12957-016-0900-y

Cited by 19 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After screening the titles and abstracts, 63 references reported on the correlation between miRNA expression and either patient survival or disease recurrence in osteosarcoma. Among these, 35 studies reported at least one unique miRNA, so a pooled analysis would not be possible [ 6 – 40 ]. Finally, 24 articles encompassing 30 studies were include in the meta-analysis [ 3 – 5 , 41 – 61 ] (Figure 1 ).…”

Section: Resultsmentioning

confidence: 99%

MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

IntroductionThis study aimed to elucidate the prognostic value of microRNAs (miRNAs) in patients with osteosarcoma.Materials and MethodsStudies were recruited by searching PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang data-bases (final search update conducted January 2017). Eligible studies were identified and the quality was assessed using multiple search strategies.ResultsA total of 55 articles that investigated the correlation between miRNA expression and either patient survival or disease recurrence in osteosarcoma was initially identified. Among these, 30 studies were included in the meta-analysis. The results of our meta-analysis revealed that elevated levels of miR-21, miR-214, miR-29, miR-9 and miR-148a were associated with poor prognosis in osteosarcoma. Additionally, downregulated miR-382, miR26a, miR-126, miR-195 and miR-124 expression indicated poor prognosis in osteosarcoma.ConclusionsmiRNAs may act as independent prognostic factors in patients with osteosarcoma and are useful in stratifying risk.

show abstract

Section: Resultsmentioning

confidence: 99%

MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Clinically, OS presents local pain and swelling with occasional joint dysfunction. 12 As our knowledge of the molecular pathogenesis of OS expands, potential therapeutic targets are being identified. In addition to surgery, chemotherapy, and radiotherapy, the comprehensive treatment of OS also includes molecular targeted therapy, immunotherapy, gene therapy, embolization, radiofrequency ablation, and stem cell therapy.…”

Section: Discussionmentioning

confidence: 99%

“…11 Current treatments for OS are associated with significant morbidity, and a period of there is a real need to optimize current treatment strategies and to develop novel approaches for treating OS. 12 As our knowledge of the molecular pathogenesis of OS expands, potential therapeutic targets are being identified. 13 Through analysis by GEO database and R2 chip analysis platform, we obtained three genes (CLEC5A, ALOX5AP, and RNASE3) associated with OS metastasis.…”

Section: Os Derives From Primitive Bone-forming Mesenchymal Cells and Ismentioning

confidence: 99%

Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A

Jin

Chen

Líu

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

ObjectiveTo screen the gene related to osteosarcoma (OS) metastasis and the molecular mechanism.MethodsGEO database and R2 chip analysis platform were used to screen genes related to OS metastasis. UCSC gene browser was used to find the transcription factor (TF) of CLEC5A. The mRNA level and protein expression of CLEC5A in OS tissues and normal tissues were determined by RT‐PCR and Western blotting, respectively. OS cell lines MG‐63 were transfected with CEBPB recombinant plasmid. After transfection, the expression of CLEC5A in MG‐63 cells was determined and the cell proliferation situation was determined by clone formation assay.ResultsThree genes CLEC5A, ALOX5AP, and RNASE3 were obtained, and CLEC5A has the highest correlation with OS. CLEC5A has screened the gene related to OS metastasis, and CEBPB can be taken as TF regulating downstream gene CLEC5A. CEBPB can regulate the downstream CLEC5A as transcription factor. The relative mRNA level and protein expression of CLEC5A in OS tissues were significantly higher than those in normal tissues. CLEC5A can prevent OS metastasis. Transfection of CEBPB increased the expression of CLEC5A in MG‐63 cells and also inhibited the proliferation of OS.ConclusionCEBPB can inhibit the proliferation of OS cells via regulating the expression of CLEC5A.

show abstract

“…Another study showed that ectopic expression of miR-212 induces apoptotic death in T-ALL cells 9. Downregulation of miR-452 occurs in several cancer types such as non-small cell lung cancer (NSCLC)10 and osteosarcoma11 and shows a poor prognostic impact on patient survival. In vitro studies demonstrated that miR-452 exhibits anti-invasive activity in NSCLC12 and prostate cancer 13.…”

Section: Introductionmentioning

confidence: 99%

Microrna-452 Exerts Growth-Suppressive Activity against T-Cell Acute Lymphoblastic Leukemia

Wang

Guo

Zhu

et al. 2018

Journal of Investigative Medicine

View full text Add to dashboard Cite

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer. Although microRNA (miR)-452 serves as a tumor suppressor in multiple solid tumors, its expression and function in hematological cancers including T-ALL is largely unknown. We measured the expression of miR-452 in 38 T-ALL and 22 normal lymph node samples by real-time PCR analysis. The methylation levels in the promoter of miR-452 were determined using MethyLight assay. The effects of miR-452 overexpression on proliferation, cell cycle distribution, and tumorigenesis were explored. It was found that miR-452 expression levels were significantly lower in T-ALL specimens than in normal lymph node biopsies (P=0.0079). T-ALL specimens had a significantly higher methylation level in the promoter of miR-452 than normal lymph node tissues (P=0.0014). Consistently, miR-452 was downregulated in Jurkat and Molt-4 T-ALL cells, whose expression was restored after treatment with a demethylation agent 5-aza-2'-deoxycytidine. Ectopic expression of miR-452 inhibited the proliferation of Jurkat and Molt-4 cells and induced a G0/G1 cell cycle arrest. Overexpression of miR-452 suppressed the protein expression of BMI1 in T-ALL cells. Rescue experiments revealed that overexpression of BMI1 partially reversed the growth-suppressive effect of miR-452 on T-ALL cells. Xenograft tumor studies confirmed that overexpression of miR-452 suppressed tumor growth in nude mice and reduced the expression of BMI1. Collectively, miR-452 is epigenetically silenced and targets BMI1 to exert a growth suppressive activity in T-ALL. Restoration of miR-452 expression may represent a promising therapeutic strategy for this malignancy.

show abstract

RETRACTED ARTICLE: Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma

Cited by 19 publications

References 40 publications

MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis

MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis

Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A

Microrna-452 Exerts Growth-Suppressive Activity against T-Cell Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About